U.S. government purchases 1.4 million doses of REGEN-COV antibodies

A few days ago, Regeneron announced that the U.
S.
Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase an additional 1.
4 million doses of antibody cocktail therapy REGEN-COV (casirivimab and imdevimab) for the treatment and prevention of new coronary pneumonia.
, The total purchase price is up to 2.
94 billion US dollars
.

According to this newly reached purchase agreement, Regeneron will supply an additional 1.
4 million doses of 1.
200 mg REGEN-COV to the US official.
The purchase price is US$2.
100 (approximately RMB 13,000) per dose.
The deadline for delivery is January 31, 2022.
Day
.

REGEN-COV is composed of monoclonal antibodies casirivimab and imdevimab.
Monoclonal antibodies are artificially manufactured proteins in laboratories that can mimic the human body’s own immune system and enable patients to produce resistance to harmful pathogens (such as SARS-CoV-2 new coronavirus) Ability
.

In this regard, Leonard S.
Schleifer, MD, President and CEO of Regeneron, said, “This new crown pneumonia pandemic has lasted for more than one and a half years, but there are still too many people hospitalized and died due to COVID-19
.

In November 2020, REGEN-COV received the FDA Emergency Use Authorization (EUA), which can be used to treat high-risk groups of people who have recently been diagnosed with mild to moderate COVID-19, including those who have tested positive for the new coronavirus and are at high risk of development.
Severe COVID-19 and/or hospitalization, children and adult patients 12 years and older, weighing at least 40 kg
.

Schleifer said that the clinical demand for REGEN-COV in the market is increasing, and Regeneron will provide additional doses for the US government
.

Reference source: REGENERON ANNOUNCES NEW US GOVERNMENT AGREEMENT TO PURCHASE ADDITIONAL DOSES OF REGEN-COV™ (CASIRIVIMAB AND IMDEVIMAB) ANTIBODY COCKTAIL